⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23602016 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL18035651 | 0.97 | — | — | |
| SCHEMBL3249011 | 0.93 | — | — | |
| SCHEMBL13849408 | 0.90 | USP2 (0.36) | — | |
| SCHEMBL5118439 | 0.90 | USP2 (0.36) | — | |
| SCHEMBL18879736 | 0.90 | USP2 (0.36) | — | |
| Hydrochloric Acid SCHEMBL23175096 | 0.90 | — | — | |
| SCHEMBL18610573 | 0.90 | USP2 (0.36) | — | |
| SCHEMBL12361074 | 0.90 | USP2 (0.36) | — | |
| SCHEMBL19242261 | 0.90 | USP2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| US-12325697-B2 | CBL-B modulators and uses thereof | NIMBUS CLIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| CN-117858707-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117858865-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-3810614-B1 | BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| EP-3822262-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| EP-4319756-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2024010772-A1 | NLRP3 INHIBITORS | KODIAK SCIENCES INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-8115006-B2 | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| EP-2019572-B1 | Assembly substrate and method of manufacturing the same | TDK CORP (JP) | 2012-02-01 | — | — | EP | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20100063293-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA ,LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2093223-A1 | PROCESS FOR PRODUCTION OF ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2009-08-26 | — | — | EP | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20070160771-A1 | Electrically-conductive plastic hangers | ENGINEERED PRODUCTS AND SERVICES, INC. | 2007-07-12 | — | — | US | disclosed |
| US-6444677-B2 | TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. | PFIZER INC. | 2002-09-03 | — | — | US | disclosed |
| EP-1106614-A1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
| US-4242359-A | ALKYL AND CYCLOALKYL SECONDARY AMINES | CORNELL RESEARCH FOUNDATION, INC. (US) | 1980-12-30 | — | — | US | disclosed |